Host, technical, and environmental factors affecting QuantiFERON-TB Gold In-Tube performance in children below 5 years of age
- PMID: 36402803
- PMCID: PMC9675832
- DOI: 10.1038/s41598-022-24433-w
Host, technical, and environmental factors affecting QuantiFERON-TB Gold In-Tube performance in children below 5 years of age
Abstract
Interferon-gamma release assays performance can be impaired by host-related, technical and environmental factors, but data in young children are limited. We performed a cross-sectional study of children < 5 years-of-age at risk of tuberculosis (TB), using QuantiFERON-TB Gold In-Tube (QFT-GIT) assays. The impact of the following was evaluated: (i) host-related [age; hematological parameters; erythrocyte sedimentation rate (ESR); C-reactive protein (CRP); and tobacco smoke exposure (TSE) based on serum cotinine concentrations], (ii) technical (pre-analytical delay) and (iii) environmental factors (annual season; monthly temperatures). Of 204 children, 35 (17.2%) were diagnosed with latent TB infection or TB disease. QFT-GIT results were indeterminate in 14 (6.9%) patients. In multivariate analysis, younger age and higher ESR were associated with lower positive control responses (beta: 0.247, p = 0.002 and - 0.204, p = 0.007, respectively), and increasing age was associated with lower rates of indeterminate QFT-GIT results [OR (95% CI) 0.948 (0.903-0.996) per month, p = 0.035]. In children with positive QFT-GIT results, average monthly temperatures correlated with antigen responses (r = 0.453, p = 0.020); also, antigen responses were lower in winter than in other seasons (p = 0.027). Serum cotinine concentrations determined in a subgroup of patients (n = 41) indicated TSE in 36 (88%), positive control responses being lower in children with TSE (p = 0.034). In children < 5 years-of-age, young age, elevated ESR, temperature, annual season and TSE can affect the performance of QFT-GIT assays.
© 2022. The Author(s).
Conflict of interest statement
Dr. Marc TEBRUEGGE has received QuantiFERON assays at reduced pricing or free of charge for TB diagnostics projects from the manufacturer (Cellestis/Qiagen) in the past, and has received support for conference attendance from Cepheid. The manufacturers had no influence on the study design, data collection, analysis or interpretation, writing of the manuscript or decision to submit the data for publication. The rest of authors have no conflicts of interest to disclose.
Figures


Similar articles
-
Comparison of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold-Plus in the Diagnosis of Mycobacterium tuberculosis Infections in Immunocompromised Patients: a Real-World Study.Microbiol Spectr. 2022 Apr 27;10(2):e0187021. doi: 10.1128/spectrum.01870-21. Epub 2022 Mar 2. Microbiol Spectr. 2022. PMID: 35234509 Free PMC article.
-
Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube Interferon Gamma Release Assays in Patients at Risk for Tuberculosis and in Health Care Workers.J Clin Microbiol. 2018 Jun 25;56(7):e00614-18. doi: 10.1128/JCM.00614-18. Print 2018 Jul. J Clin Microbiol. 2018. PMID: 29743310 Free PMC article.
-
Evaluation of Standard E TB-Feron Enzyme-Linked Immunosorbent Assay for Diagnosis of Latent Tuberculosis Infection in Health Care Workers.J Clin Microbiol. 2019 Nov 22;57(12):e01347-19. doi: 10.1128/JCM.01347-19. Print 2019 Dec. J Clin Microbiol. 2019. PMID: 31533984 Free PMC article.
-
Fourth-Generation QuantiFERON-TB Gold Plus: What Is the Evidence?J Clin Microbiol. 2020 Aug 24;58(9):e01950-19. doi: 10.1128/JCM.01950-19. Print 2020 Aug 24. J Clin Microbiol. 2020. PMID: 32493779 Free PMC article. Review.
-
Comparing the Diagnostic Performance of QuantiFERON-TB Gold Plus to Other Tests of Latent Tuberculosis Infection: A Systematic Review and Meta-analysis.Clin Infect Dis. 2021 Sep 7;73(5):e1116-e1125. doi: 10.1093/cid/ciaa1822. Clin Infect Dis. 2021. PMID: 33289038 Free PMC article.
Cited by
-
Risk factors for latent tuberculosis infection clustering among the elderly: a population-based cross-sectional study in Eastern China.BMC Infect Dis. 2025 Mar 17;25(1):368. doi: 10.1186/s12879-025-10743-7. BMC Infect Dis. 2025. PMID: 40098074 Free PMC article.
-
Screening for latent tuberculosis: the way forward for tuberculosis elimination.Reumatologia. 2022;60(6):363-365. doi: 10.5114/reum.2022.123666. Epub 2022 Dec 30. Reumatologia. 2022. PMID: 36683832 Free PMC article. No abstract available.
References
-
- National Institute for Health and Clinical Excellence. Tuberculosis. NICE guideline. https://www.nice.org.uk/guidance/ng33 (2016).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous